(Q33343690)

English

Liposomal daunorubicin (DaunoXome) plus dexamethasone for patients with multiple myeloma. A phase II International Oncology Study Group study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Liposomal daunorubicin (DaunoXome) plus dexamethasone for patients with multiple myeloma. A phase II International Oncology Study Group study (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Ann F Mohrbacher

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Stephanie A Gregory

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Don A Gabriel

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Jason M Rusk

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Francis J Giles

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

language of work or name

0 references

publication date

1 May 2002

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

94

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

2645-2652

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Salvage therapy for multiple myeloma: the University of Arkansas experience.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10561

21 January 2018

Long-term follow-up after high-dose therapy for high-risk multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10561

21 January 2018

Recent advances in the treatment of multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10561

21 January 2018

The treatment of multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10561

21 January 2018

Effective treatment of advanced multiple myeloma refractory to alkylating agents.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10561

21 January 2018

VAD chemotherapy as remission induction for multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10561

21 January 2018

VAD or VMBCP in severe multiple myeloma. The Groupe d'Etudes et de Recherche sur le Myélome (GERM)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10561

21 January 2018

VAD chemotherapy for refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10561

21 January 2018

A randomized study of MOD versus VAD in the treatment of relapsed and resistant multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10561

21 January 2018

VAD-based regimens as primary treatment for multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10561

21 January 2018

A randomized study of VAD therapy with either concurrent or maintenance interferon in patients with newly diagnosed multiple myeloma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10561

21 January 2018

IL2 fused to lectin-deficient ricin is toxic to human leukemia cells expressing the IL2 receptor.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10561

21 January 2018

Infused vincristine and adriamycin with high dose methylprednisolone (VAMP) in advanced previously treated multiple myeloma patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10561

21 January 2018

VAD regimen in the treatment of resistant multiple myeloma: slow or fast infusion?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10561

21 January 2018

Cyclophosphamide, etoposide, vincristine, adriamycin, and dexamethasone (CEVAD) regimen in refractory multiple myeloma: an International Oncology Study Group (IOSG) phase II protocol

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10561

21 January 2018

The long-term complications of chemotherapy in childhood genitourinary tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10561

21 January 2018

The biochemistry of P-glycoprotein-mediated multidrug resistance

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10561

21 January 2018

Phase I and pharmacologic study of liposomal daunorubicin (DaunoXome).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10561

21 January 2018

Liposome-encapsulated daunorubicin for PGP-related multidrug resistance.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10561

21 January 2018

Liposomal daunorubicin in advanced Kaposi's sarcoma: a phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10561

21 January 2018

Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10561

21 January 2018

Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10561

21 January 2018

A phase II study of DaunoXome in advanced urothelial transitional cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10561

21 January 2018

Multidrug-resistant acute leukemia cells are responsive to prolonged exposure of daunorubicin: implications for liposome-encapsulated daunorubicin.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10561

21 January 2018

Multiple myeloma and Kaposi's sarcoma: what is the association?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10561

21 January 2018

Multiple myeloma associated with Kaposi sarcoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10561

21 January 2018

The role of vascular endothelial growth factor (VEGF) in AIDS-related Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10561

21 January 2018

A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10561

21 January 2018

Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10561

21 January 2018

Treatment of myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10561

21 January 2018

Oral idarubicin as a single agent therapy in patients with relapsed or resistant multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10561

21 January 2018

VAD-Cyclosporine Therapy for VAD-Resistant Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10561

21 January 2018

Prospective randomised study of double hemi-body irradiation with and without subsequent maintenance recombinant alpha 2b interferon on survival in patients with relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10561

21 January 2018

VAD chemotherapy--toxicity and efficacy--in patients with multiple myeloma and other lymphoid malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10561

21 January 2018

Combination chemotherapy with vincristine, doxorubicin, dexamethasone for refractory or relapsing multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10561

21 January 2018

VAD-PECC regimen in the treatment of advanced-stage multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10561

21 January 2018

A phase I/II trial of Z-Dex (oral idarubicin and dexamethasone), an oral equivalent of VAD, as initial therapy at diagnosis or progression in multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10561

21 January 2018

Phase III study comparing vincristine, doxorubicin (Adriamycin), and dexamethasone (VAD) chemotherapy with VAD plus recombinant interferon alfa-2 in refractory or relapsed multiple myeloma. An Eastern Cooperative Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10561

21 January 2018

Adriamycin cardiotoxicity in man

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10561

21 January 2018

Structural requirements for anthracycline-induced cardiotoxicity and antitumor effects

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10561

21 January 2018

Anthracycline-induced cardiotoxicity in children with malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10561

21 January 2018

Clinical modulation of multidrug resistance in multiple myeloma: effect of cyclosporine on resistant tumor cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10561

21 January 2018

Demonstration of differences in drug resistance by direct testing of DNA excision repair activity following standard and liposomal daunorubicin exposure in normal paediatric marrow using high resolution CLSM.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10561

21 January 2018

Liposomal daunorubicin:in vitro andin vivo efficacy in multiple myeloma

2 references

https://api.crossref.org/works/10.1002%2FCNCR.10561

21 January 2018

https://api.crossref.org/works/10.1002%2FCNCR.10561

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II studies with DaunoXome in patients with nonresectable hepatocellular carcinoma: clinical and pharmacokinetic outcomes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10561

21 January 2018

Early evaluation of liposomal daunorubicin (DaunoXome, Nexstar) in the treatment of relapsed and refractory lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10561

21 January 2018

Phase I study of liposomal daunorubicin in patients with acute leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10561

21 January 2018

Kaposi's sarcoma in patient with multiple myeloma, sideroblastic anaemia, and T-lymphocyte abnormalities

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10561

21 January 2018

Kaposi's sarcoma-associated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10561

21 January 2018

Life-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10561

21 January 2018

In vitro cellular accumulation and cytotoxicity of liposomal and conventional formulations of daunorubicin and doxorubicin in resistant K562 cells.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10561

7 January 2021

based on heuristic

inferred from DOI database lookup

Modulation of doxorubicin resistance in multidrug-resistant cells by liposomes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10561

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.10561

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33343690&oldid=1976644436"